Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DEC–205 (CD205) is a type I transmembrane glycoprotein receptor primarily expressed on dendritic cells and thymic epithelial cells. It functions as an endocytic receptor mediating efficient uptake of extracellular antigens for presentation to T cells, particularly cross-presentation to CD8+ T cells. It also recognizes apoptotic and necrotic cells. Targeting antigens via DEC–205 is being explored in vaccine development and immune tolerance induction.
Antibody-antigen fusion proteins directed at DEC–205 facilitate antigen uptake and presentation by dendritic cells, leading to T cell activation and immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dendritic Cell Receptor DEC–205 (CD205).